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I. Introduction
Adenoviruses are a common
cause of upper respiratory tract
infections in children and the
source of acute respiratory
disease outbreaks among
military recruits. Named after
the human adenoid tissue it was
first isolated in, the adenoviridae
are non-enveloped, doublestranded DNA viruses with over
50 serotypes1. Yet to date
vaccines have been developed
for only two serotypes, and no
adenovirus antiviral drugs have
been approved by the FDA,
highlighting the need for more
research.
In virus research, detection the
presence of a particular virus is
of especial interest when
developing animal or cell
models. As human pathogens
often do not infect common lab
animals or certain cell types,
researchers must alter either the

II. Methods
host or the virus in order to
produce a working model. This
may involve genetically
engineering host cells to express
a need receptor protein, or
passaging cells multiple times in
the presence of the virus,
anticipating that the virus will
evolve pathogenicity. Thus, the
ability to detect if a virus has
replicated in a host is key to
determining the viability of a cell
or animal model.
Here we attempt to develop an
ELISA detection assay for
adenovirus d1327. ELISA assay is
especially usefully for virus
detection because of its
specificity and easily identifiable
positive result. Antibodies
specific to the virus of interest
bind the virus to the plate, while
enzyme conjugates provide a
visible signal if the virus is
present.

A plate layout as well as needed
reagents and blocking times were
determined the previous year.
However, in order to select the
correct antibodies to be used in the
assay, the type of the virus had to
be determined. There is little
information in the literature which
confirms the type of d1327, with
the type determined to be either
AdV 1 or AdV 5. In order to remedy
this, the virus needed to be

III. Results
identified by treating a plaque
assay of d1327 with antibodies
towards type 1 and type 5. The
proper dilution and incubation
times for the plaque assay must
first be determined, and then the
virus sample can be challenged
with the different antibodies. Once
the virus type is determined, the
assay can be constructed using the
correct antibodies.

We ultimately settled on using a
crystal violet stain with careful
removal of the monolayer with a
fine-tipped vacuum attachment.
Once the monolayer was cleanly
removed and the wells stained,
cytopathic effect was observed in
the monolayer. However, the CPE
was diffuse and did not form
individual plaques.

Figure 4. Image of plaque assay with d1327 adenovirus. CPE is observed in the first three wells,
but no discrete plaques are found.

Figure 2. Depiction of sandwich ELISA protocol that will be used to identify d1327 adenoviridae.
Image credit Jeffrey M. Vinocur.

Figure 1. Transmission electron microscope image of adenoviridae particles
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We had difficulty getting definitive
results from the plaque assay. The
first difficulty was removing the
agarose plug without disturbing the
monolayer. Removal by spatula or
vacuum have the potential to be
messy. We then attempted to do a
live staining with neutral red added
directly to the agarose, but this
failed to visualize any plaques.

Figure 3. Example of plaque
assay using crystal violet stain.
Each plaque is assumed to be
the result of a single virus.

IV. Conclusions
Development of the assay was not
limited by the inability to produce a
potential protocol for the ELISA, but
rather from difficulty identifying
the type of virus being tested. In
order to remedy the diffuse CPE, a
higher concentration agar could be
used to cover the monolayer, which

should help restrict the virus from
infecting neighboring cells.
However, an alternative to the
plaque assay, the virus
neutralization assay, may be a
better option. Once the virus type
is determined, our ELISA protocol
can be tested and optimized.
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